LND topic: biopharma page 1

biopharma

Jazz Pharma: A Hot Pick for Smart Buyers

March 28, 2026

The biopharma firm Jazz Pharmaceuticals is making headlines because its shares have surged nearly 50 percent in the last year. The company focuses on drugs for sleep disorders and cancer, with two main products—Xywav and Xyrem—helping people who suffer from narcolepsy. Those medicines have become th

finance

Ligand’s Stock Rises After Bank of America Adds a Buy Rating

March 11, 2026

Bank of America has added Ligand Pharmaceuticals to its list of stocks it recommends buying, setting a new price target at $244. The move comes as the bank highlights Ligand’s business model, which focuses on high‑margin products and a lower level of risk compared to many other biopharma companies.

science

Boosting Tiny Factories for Better Medicines

January 18, 2026

CHO cells are like tiny factories. They make important medicines that help people fight diseases. But they are not very efficient. Scientists have been trying to make them better for years. They have tried many different methods. Some of these methods work well. But the results are not as good as ho

business

A New Era for MannKind: What's Next in 2026?

January 8, 2026

MannKind, a company focused on treating long-term illnesses, had a strong finish to 2025. They acquired another company, scPharmaceuticals, and made over $100 million in their last quarter. This success has set the stage for an exciting 2026, with two major products potentially hitting the market.

finance

Market Moves: Big Wins and Losses in the World of Stocks

January 5, 2026

The stock market had a wild ride recently, with some companies seeing huge gains while others took a big hit. Let's break it down. Zenas BioPharma, a biotech company, saw its stock drop by more than half after their new drug showed promise in trials. The drug, obexelimab, is meant to treat a rare d

business

New Face on the Board: Pelthos Therapeutics Welcomes Finance Expert

December 24, 2025

Pelthos Therapeutics has just added a seasoned finance pro to its board. Andrew J. Einhorn, a veteran with over 40 years in the field, is now on the team. He's stepping into big roles too - Audit Committee and Compensation Committee. With his background in investment banking and leading finance team

environment

A Big Step Forward for Gannet BioChem in the Fight Against Climate Change

December 9, 2025

Gannet BioChem, a top player in the specialty chemical industry, has just hit a major milestone. They've got the green light from the Science Based Targets initiative (SBTi) for their plans to cut down on greenhouse gas emissions. This isn't just any old goal-setting; it's a big deal in the world of

science

Yeast Magic: Turning Milk Sugar into Medicines

October 29, 2025

Yeasts are tiny powerhouses. They've been helping humans make bread, beer, and wine for ages. Now, scientists are using them to make medicines too. One such yeast, Kluyveromyces lactis, is known for its work in the dairy industry. But now, it's being used in a new way. Scientists have developed a me

health

Streamlining Drug Development: The PBBM Report Game Changer

April 30, 2025

Drug development is a complex process. Companies use tools to make it easier. One such tool is the Physiologically Based Biopharmaceutics Model (PBBM). It helps guide how drugs are made and can even skip some clinical tests. This is great for both innovators and generic drug makers. However, th

health

The Hidden Dangers of Modern Medicine

April 4, 2025

The 15th European Immunogenicity Platform Open Symposium took place in Lisbon from February 22-24, 2024. This event brought together professionals from various fields, including industry, regulatory bodies, and academia. They gathered to discuss the challenges posed by the immune response to bioph